Interestingly, HRAS mutations at Q61 and G13, which are the most frequent non-RET mutation in sporadic MTC (and mutually exclusive to RET mutations) (Xu et al. 2024), have not yet been described as a mechanism of resistance to RET inhibitors. This evidence concerns the gene RET and medullary thyroid gland carcinoma.